NEW YORK, September 13, 2016 /3BL Media/ Bristol-Myers Squibb Company (NYSE:BMY) has earned a place on the prestigious Dow Jones Sustainability Index (DJSI) North America for the second consecutive year. The index recognizes public companies for outstanding performance across economic, environmental and social factors, and serves as a benchmark for investors who integrate sustainability considerations into their portfolios.
Bristol-Myers Squibb is one of eight pharmaceutical, biotechnology and life sciences companies included on the 2016 North America Index.
HOUSTON, TX and PRINCETON, NJ, June 27, 2016 /3BL Media/ – The Angola Sickle Cell Initiative, a public-private partnership of the Angola Ministry of Health, the Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI), Texas Children’s Hospital and Chevron, is teaming up with the global biopharmaceutical company Bristol-Myers Squibb to provide children with sickle cell disease in Angola with an effective medication to which many patients in the country have lacked access.
WASHINGTON, D.C., June 22, 2016 /3BL Media/ - Today, the Bristol-Myers Squibb Foundation and FSG are calling on the healthcare sector to address inequity in a new resource--Breaking the Barriers to Specialty Care: Practical Ideas to Improve Health Equity and Reduce Cost.
The UPL seeks to improve how complex topics are communicated to patients; Company launches UPL.org to make principles and tools widely available to others
PRINCETON, N.J., June 16, 2016 /3BL Media/ Bristol-Myers Squibb (NYSE:BMY) today announced its commitment to moving toward a new way of communicating with patients and caregivers: the Universal Patient Language (UPL). The UPL addresses widely voiced concerns among consumers and health care advocates that communications about medicines are not designed for an optimal patient experience.
June is National Cancer Survivor Month. The Bristol-Myers Squibb Foundation’s Bridging Cancer Care™ initiative supports community-based resources and survivorship support programs expanding to underserved populations in the U.S., with a primary focus on southeastern states with the highest lung cancer incidence and mortality in the country. By collaborating with partners such as Lung Cancer Alliance, the Foundation is promoting much-needed support for lung cancer survivors and their families.
When a business incorporates global diversity and inclusion into its philosophy, it creates good will among its employees and customers. But diversity and inclusion is also a business imperative at Bristol-Myers Squibb, recognizing that companies focusing on those ideals perform better overall.
Bristol-Myers Squibb was just honored as a Top 30 Best-of-the-Best company by the National Business Inclusion Consortium (NBIC) and the National Gay & Lesbian Chamber of Commerce (NGLCC).
For the eighth consecutive year, Bristol-Myers Squibb ranks in the top 10, ranking sixth of the 100 BestCorporate Citizens, a leading benchmark for socially responsible investors and other stakeholders published by Corporate Responsibility magazine. The company has achieved the No. 1 ranking three times, including 2009, 2012 and 2014.
We are honored and proud that Bristol-Myers Squibb is among Fast Company’s Most Innovative Companies for 2016 and that our passion for developing and delivering transformational medicines helped earn us the number two spot in the rankings’ Biotech category this year.
World Cancer Day, recognized annually on February 4, is an initiative of the Union for International Cancer Control (UICC), focused on uniting the world in the fight against cancer. Having in mind Bristol-Myers Squibb’s commitment to make a difference in the lives of patients living with cancer, we can’t think of a better opportunity for the global community to come together and to raise awareness about this devastating disease: its prevalence; what the public should know about risk factors; and the importance of education and support.
Grants will support screening and navigation, and create new strategies and models for overcoming barriers to care for low-income and minority populations
NEW YORK, February 1, 2016 /3BL Media/ – To mark National Cancer Prevention Month, the Bristol-Myers Squibb Foundation today announced eight grants totaling nearly $11.5 million that will help make lung and skin cancer screening programs, care and patient support more accessible to underserved populations. The goal is to develop, validate and sustain models that deliver equitable and optimal outcomes.